NCT00051168已完成3 期
A Long-term Safety Study of Once-daily TRAVATAN
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 502
- 试验地点
- 1
- 主要终点
- Mean Intraocular Pressure
研究概览
简要总结
Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Travatan
Experimental
Travoprost (0.004%)
干预措施: Travatan (Drug)
结局指标
主要结局
Mean Intraocular Pressure
时间窗: At 5 years.
Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)Glaucoma, Open-AngleOcular HypertensionNCT00051155Alcon Research
已完成
4 期
An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®GlaucomaOcular HypertensionNCT01664039Alcon Research104
撤回
3 期
Three Month Safety and Efficacy Study of TRAVATAN® Versus Travoprost Ophthalmic Solution, 0.004%Open Angle GlaucomaOcular HypertensionNCT01452009Alcon Research
已完成
3 期
Safety, Pharmacokinetics, Tolerability and Efficacy of Tolvaptan in Children and Adolescents With ADPKD (Autosomal Dominant Polycystic Kidney Disease)Autosomal Dominant Polycystic Kidney Disease (ADPKD)NCT02964273Otsuka Pharmaceutical Development & Commercialization, Inc.91
已完成
4 期
Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular HypertensionGlaucomaOcular HypertensionNCT00061503Alcon Research